Biohaven 관리

관리 기준 확인 2/4

Biohaven CEO는 Vlad Coric, May2022 에 임명되었습니다 의 임기는 2.5 년입니다. 는 $ 166.09M 가치에 해당하는 회사 주식의 3.15% 직접 소유합니다. 166.09M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 2.2 년입니다.

주요 정보

Vlad Coric

최고 경영자

US$6.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	2.5yrs
CEO 소유권	3.1%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	2.2yrs

최근 관리 업데이트

Recent updates

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Apr 06

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

CEO 보상 분석

Vlad Coric 의 보수는 Biohaven 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$747m
Mar 31 2024	n/a	n/a	-US$517m
Dec 31 2023	US$7m	n/a	-US$408m
Sep 30 2023	n/a	n/a	-US$465m
Jun 30 2023	n/a	n/a	-US$431m
Mar 31 2023	n/a	n/a	-US$544m
Dec 31 2022	US$7m	US$200k	-US$570m

보상 대 시장: Vlad 의 총 보상 ($USD 6.82M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 7.84M ).

보상과 수익: 회사가 수익성이 없는 동안 Vlad 의 보상이 증가했습니다.

CEO

Vlad Coric (53 yo)

2.5yrs

테뉴어

US$6,819,189

보상

Dr. Vladimir Coric, M.D., also known as Vlad, is an Independent Director at Revance Therapeutics, Inc. since March 01, 2023. He is Director at Pyramid Biosciences Inc. since August 2020. He had been Indepe...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vladimir Coric	Chairman & CEO	2.5yrs	US$6.82m	3.15% $ 166.1m
Matthew Buten	Chief Financial Officer	no data	US$2.76m	0.19% $ 10.0m
Bruce Car	Chief Scientific Officer	2.3yrs	US$2.58m	0.032% $ 1.7m
Kimberly Gentile	Senior Vice President of Clinical Operations	no data	US$2.56m	0.095% $ 5.0m
Deb Young	Director of Regulatory Affairs & Operations	1.8yrs	데이터 없음	데이터 없음
George Clark	VP & Chief Accounting Officer	no data	데이터 없음	데이터 없음
Jennifer Porcelli	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Warren Volles	General Counsel & Chief Legal Officer	no data	데이터 없음	데이터 없음
Clifford Bechtold	President	no data	데이터 없음	데이터 없음
John Tilton	Chief Commercial Officer of Rare Diseases	no data	데이터 없음	데이터 없음
Chris Barrett	Senior Vice President of Commercial Strategy	no data	데이터 없음	데이터 없음
Gilbert L'italien	Senior Vice President of GHEOR & Epidemiology	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: BHVN 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vladimir Coric	Chairman & CEO	2.5yrs	US$6.82m	3.15% $ 166.1m
Douglas Gray	Corporate Secretary & Director	no data	데이터 없음	데이터 없음
John Childs	Independent Director	2.2yrs	US$555.94k	6.44% $ 339.8m
Julia Gregory	Independent Director	2.2yrs	US$567.94k	0.026% $ 1.3m
Robert Hugin	Independent Director	2.2yrs	US$562.94k	0.013% $ 679.3k
Gregory Bailey	Independent Director	2.2yrs	US$545.94k	1.61% $ 84.9m
Michael Heffernan	Lead Independent Director	2.2yrs	US$597.94k	0.015% $ 795.9k
Richard B. Lipton	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
John Krystal	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Irina Antonijevic	Independent Director	2.2yrs	US$542.94k	0.0025% $ 132.9k
Kishan Mehta	Director	2.2yrs	US$535.94k	0.023% $ 1.2m
Gerard Sanacora	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

2.2yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: BHVN 의 이사회는 경험(평균 재직 기간 2.2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Biohaven 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Recent updates

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

New minor risk - Share price stability

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Consensus EPS estimates fall by 23%

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million.

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Now 21% overvalued after recent price rise

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Now 21% overvalued after recent price rise

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

New major risk - Financial position

Director exercised options and sold US$460k worth of stock

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Price target increased by 11% to US$33.17

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Price target increased by 7.8% to US$30.00

Price target increased by 7.4% to US$29.00

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Independent Director recently bought US$402k worth of stock

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Independent Director recently bought US$922k worth of stock

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Independent Director recently bought US$2.0m worth of stock

New minor risk - Share price stability

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

High number of new and inexperienced directors

Biohaven Ltd: Assessing The Spinoff

Biohaven Non-GAAP EPS of -$1.25

Chairman & CEO recently bought US$2.1m worth of stock

Biohaven Ltd. Advances Development of the MoDE Platform Technology Licensed From Yale University

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령